GLP-1 Price Guide Compare prices
Safety · June 1, 2026

Why Pharmacy Transparency Matters for GLP-1 Patients

The pharmacy compounding your medication determines its quality. Knowing the partner pharmacy is the single most important transparency signal.

Safety & RegulationJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

Three Reasons Pharmacy Matters

  1. Quality varies by pharmacy. Sterile injectable compounding requires specific standards. Pharmacies maintaining USP <797> and USP <800> compliance with regular state inspections produce higher-quality preparations.
  2. Licensure verification. A named pharmacy can be verified through the State Board of Pharmacy. Unnamed or generic 'partner pharmacy' references can't be verified.
  3. FDA registration. 503B facilities are listed in the FDA 503B Outsourcing Facility Registry. Listing confirms FDA-registered status.

Transparency Spectrum

Disclosure levelWhat patients seeRisk level
Full pre-purchase disclosureNamed pharmacies, state, license number verifiableLow (NexLife model)
Post-prescription disclosurePharmacy identified on shipping/label onlyMedium
Generic 'partner network''Our partner pharmacies' with no namesMedium/High
No disclosurePharmacy not identified pre or postHigh

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.